France's Sanofi SA said it would appeal a rejection by U.S. regulators of its new multiple-sclerosis drug Lemtrada.. The Food and Drug Administration expressed concern over serious side effects of the drug and the design of Sanofi's clinical trials. Lemtrada was approved for sale in Europe, Canada and Australia earlier this year.. The U.S. decision...
  